How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?  

Age is relative and there are numerous studies showing that well-performing elderly patients can tolerate systemic therapy to small cell lung cancer. That being said, I first assess whether additional cancer therapy is within the goals of care for each individual patient. While the outcomes for DLL3...

For me, the numerical age is not what is important but rather the patient's comorbidities and performance status. For example, we know that tarlatamab can have neuro-toxicity in the form of ICANS and therefore, the mental status/cognitive ability for me is very important to assess. As with all patie...

I do not distinguish based on age. I have treated patients in their 80s with this agent with no significant increase in adverse events.